Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
26-29 October, 2025
ISPE Annual MeetingISPE Annual Meeting
Not Confirmed
Not Confirmed
26-29 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
26-29 October, 2025
ISPE Annual MeetingISPE Annual Meeting
Industry Trade Show
Not Confirmed
26-29 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-re-expanding-our-cdmo-capabilities-to-meet-the-next-wave-of-complex-therapies-starting-with-oncology
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

23 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/doer-biologics-announces-first-patient-dosed-in-phase-2-study-of-dr10624-for-treatment-of-metabolic-dysfunction-associated-steatotic-liver-disease-and-metabolic-dysfunction-associated-steatohepatitis-302435526.html

09 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/doer-biologics-completes-enrollment-of-the-phase-2-clinical-study-of-dr10624-for-treatment-of-severe-hypertriglyceridemia-302396512.html

30 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/doer-biologics-announces-first-patient-dosed-in-phase-2-study-of-dr10624-for-treatment-of-severe-hypertriglyceridemia-302262301.html

05 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/zhejiang-doer-biologics-completes-enrollment-of-the-phase-1b2a-trial-evaluating-dr10624-in-obese-subjects-with-modest-hypertriglyceridemia-302189900.html

01 Aug 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/doer-biologics-announces-first-subject-dosed-in-phase-i-12-week-multiple-ascending-dose-mad-clinical-trial-of-dr10624-and-received-ind-approval-from-nmpa-301890125.html
ABOUT THIS PAGE